The Core Transcriptome of Mammalian Placentas and the Divergence of Expression with Placental Shape
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Unc93b Antibody (Pab)
21.10.2014Unc93b antibody (pAb) Rabbit Anti -Human/Mouse/Rat Unc93b Instruction Manual Catalog Number PK-AB718-4553 Synonyms Unc93b Antibody: Unc93b1, homolog of C. elegans Unc93 Description The endoplasmic reticulum (ER) protein Unc93b, a human homolog of the C. elegans Unc93 gene, was initially identified by a forward genetic screen using N-ethyl-N-nitrosourea where a histidine- to-arginine substitution in Unc93b caused defects in Toll-like receptor (TLR) 3, 7 and 9 signaling. Unlike Unc93a, another homolog of the C. elegans Unc93 gene whose function is unknown, Unc93b specifically interacts with TLR3, 7 and 9; the histidine-to-arginine point mutation used to identify Unc93b abolishes this interaction. Mice carrying this point mutation are highly susceptible to infection with a number of viruses, indicating that Unc93b plays an important role in innate immunity. Multiple isoforms of Unc93a are known to exist. This antibody will not cross-react with Unc93a. Quantity 100 µg Source / Host Rabbit Immunogen Unc93b antibody was raised in rabbits against a 19 amino acid peptide from near the amino terminus of human Unc93b. Purification Method Affinity chromatography purified via peptide column. Clone / IgG Subtype Polyclonal antibody Species Reactivity Human, Mouse, Rat Specificity Multiple isoforms of Unc93a are known to exist. This antibody will not cross-react with Unc93a. Formulation Antibody is supplied in PBS containing 0.02% sodium azide. Reconstitution During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. -
Open Full Page
Research Article Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization Go¨ran Jo¨nsson,1 Tara L. Naylor,5 Johan Vallon-Christersson,1 Johan Staaf,1 Jia Huang,5 M. Renee Ward,5 Joel D. Greshock,5 Lena Luts,4 Ha˚kan Olsson,1 Nazneen Rahman,6 Michael Stratton,6 Markus Ringne´r,3 A˚ke Borg,1,2 and Barbara L. Weber5 1Department of Oncology, University Hospital; 2Lund Strategic Research Center for Stem Cell Biology and Cell Therapy and 3Department of Theoretical Physics, Lund University; and 4Department of Pathology, University Hospital, Lund, Sweden; 5Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania; and 6Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom Abstract of additional predisposing genes, although technical limitations Mutations in BRCA1 and BRCA2 account for a significant and the complexity of BRCA gene regulation and mutation proportion of hereditary breast cancers. Earlier studies have spectrum can probably explain why some disease-causing muta- shown that inherited and sporadic tumors progress along tions are missed (2). BRCA1 and BRCA2 function as classic tumor different somatic genetic pathways and that global gene suppressor genes with frequent loss of the wild-type allele in expression profiles distinguish between these groups. To tumors of mutation carriers. The BRCA1 protein has been determine whether genomic profiles similarly discriminate implicated in a broad range of cellular functions, including repair among BRCA1, BRCA2, and sporadic tumors, we established of double-strand breaks by homologous recombination, cell cycle DNA copy number profiles using comparative genomic checkpoint control, chromatin remodeling, and transcriptional hybridization to BAC-clone microarrays providing <1 Mb regulation. -
Supplementary Data
SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche). -
Monoclonal Antibodies
NOTE Clinical Pathology Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies Masaya IGASE1), Yuki MORINAGA1), Masahiro KATO2), Toshihiro TSUKUI2), Yusuke SAKAI3), Masaru OKUDA4) and Takuya MIZUNO1)* 1)Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1, Yoshida, Yamaguchi-shi, Yamaguchi 753-8511, Japan 2)Nippon Zenyaku Kogyo Co., Ltd., 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, Fukushima 963-0196, Japan 3)Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1, Yoshida, Yamaguchi-shi, Yamaguchi 753-8511, Japan 4)Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1, Yoshida, Yamaguchi-shi, Yamaguchi 753-8511, Japan ABSTRACT. DEP domain-containing 1B (DEPDC1B) is involved in the regulation of cell de- J. Vet. Med. Sci. adhesion and actin cytoskeleton activity during the G2/M transition of the cell cycle, and its 82(4): 483–487, 2020 overexpression has been proven to be associated with cancer progression in several human cancers. Canine DEPDC1B was identified as a gene that was overexpressed in canine lymphoma doi: 10.1292/jvms.19-0667 tissues in our previous study. However, in dogs, the protein expression of DEPDC1B remains to be determined due to the lack of a specific monoclonal antibody. Here, we developed rat monoclonal antibodies against canine DEPDC1B and characterized their applicability for immunodetection Received: 12 December 2019 assays. Our findings demonstrated that these antibodies are functional and can be important tools Accepted: 20 February 2020 to investigate the precise role of DEPDC1B in canine tumors. Advanced Epub: 6 March 2020 KEY WORDS: antibody, cancer, DEP domain-containing 1B, dog The DEP domain-containing 1B (DEPDC1B) gene was recently identified and localized at human chromosome 5 (5q12.1). -
Supplemental Table 1: Genes That Show Altered Expression in Hepg2 Cells in the Presence of Exogenously Added Let-7
Supplemental Table 1: Genes that show altered expression in HepG2 cells in the presence of exogenously added let-7 Gene Title Gene Symbol RefSeq Transcriptp- IDvalue(TREAp-TMENTvalue(Let7bS) - negativLog2 Reatio control1) (Let7b - negativp-value(Let7be control1) - negativLog2 Reatio control2) (Let7b - negative control2) aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-reductase) AKR1D1 NM_005989 3.28E-12 2.52E-12 -3.85007 3.59E-12 -3.73727 lin-28 homolog B (C. elegans) LIN28B NM_001004317 6.13E-15 8.29E-15 -3.29879 1.55E-15 -3.79656 high mobility group AT-hook 2 /// high mobility group AT-hook 2 HMGA2 NM_001015886 /// NM_0034833.74E-14 /// NM_0034844.29E-14 -3.06085 4.56E-14 -3.04538 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 HECW2 NM_020760 1.27E-13 6.65E-13 -2.94724 4.47E-12 -2.50907 cell division cycle 25A CDC25A NM_001789 /// NM_2015672.01E-11 7.32E-11 -2.88831 1.99E-11 -3.22735 hypothetical protein FLJ21986 FLJ21986 NM_024913 1.05E-09 5.19E-10 -2.80277 1.18E-09 -2.61084 solute carrier family 2 (facilitated glucose transporter), member 3 SLC2A3 NM_006931 1.59E-13 3.49E-13 -2.78111 1.84E-12 -2.41734 Transcribed locus --- --- 2.58E-13 1.08E-13 -2.59794 1.69E-13 -2.50248 Hypothetical protein LOC145786 LOC145786 --- 4.23E-12 1.07E-11 -2.58849 3.00E-12 -2.88135 Dicer1, Dcr-1 homolog (Drosophila) DICER1 NM_030621 /// NM_1774381.06E-08 4.37E-09 -2.5442 4.49E-09 -2.53796 mannose-binding lectin (protein C) 2, soluble (opsonic defect) MBL2 NM_000242 9.73E-10 1.48E-09 -2.53211 9.84E-10 -2.62363 cell -
Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing -
Atypical Solute Carriers
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1346 Atypical Solute Carriers Identification, evolutionary conservation, structure and histology of novel membrane-bound transporters EMELIE PERLAND ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-513-0015-3 UPPSALA urn:nbn:se:uu:diva-324206 2017 Dissertation presented at Uppsala University to be publicly examined in B22, BMC, Husargatan 3, Uppsala, Friday, 22 September 2017 at 10:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Faculty examiner: Professor Carsten Uhd Nielsen (Syddanskt universitet, Department of Physics, Chemistry and Pharmacy). Abstract Perland, E. 2017. Atypical Solute Carriers. Identification, evolutionary conservation, structure and histology of novel membrane-bound transporters. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1346. 49 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0015-3. Solute carriers (SLCs) constitute the largest family of membrane-bound transporter proteins in humans, and they convey transport of nutrients, ions, drugs and waste over cellular membranes via facilitative diffusion, co-transport or exchange. Several SLCs are associated with diseases and their location in membranes and specific substrate transport makes them excellent as drug targets. However, as 30 % of the 430 identified SLCs are still orphans, there are yet numerous opportunities to explain diseases and discover potential drug targets. Among the novel proteins are 29 atypical SLCs of major facilitator superfamily (MFS) type. These share evolutionary history with the remaining SLCs, but are orphans regarding expression, structure and/or function. They are not classified into any of the existing 52 SLC families. -
WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq Data
RESEARCH ARTICLE Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq Data David L. A. Wood1*, Katia Nones1, Anita Steptoe1, Angelika Christ1, Ivon Harliwong1, Felicity Newell1, Timothy J. C. Bruxner1, David Miller1, Nicole Cloonan2, Sean M. Grimmond3,1 1 Queensland Centre for Medical Genomics, University of Queensland, Brisbane, Australia, 2 QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia, 3 Translational Research Centre, University of Glasgow, Glasgow, Scotland a11111 * [email protected] Abstract Genetic variation modulates gene expression transcriptionally or post-transcriptionally, and OPEN ACCESS can profoundly alter an individual’s phenotype. Measuring allelic differential expression at Citation: Wood DLA, Nones K, Steptoe A, Christ A, heterozygous loci within an individual, a phenomenon called allele-specific expression Harliwong I, Newell F, et al. (2015) (ASE), can assist in identifying such factors. Massively parallel DNA and RNA sequencing Recommendations for Accurate Resolution of Gene and Isoform Allele-Specific Expression in RNA-Seq and advances in bioinformatic methodologies provide an outstanding opportunity to mea- Data. PLoS ONE 10(5): e0126911. doi:10.1371/ sure ASE genome-wide. In this study, matched DNA and RNA sequencing, genotyping ar- journal.pone.0126911 rays and computationally phased haplotypes were integrated to comprehensively and Academic Editor: I. King Jordan, Georgia Institute of conservatively quantify ASE in a single human brain and liver tissue sample. We describe a Technology, UNITED STATES methodological evaluation and assessment of common bioinformatic steps for ASE quantifi- Received: February 3, 2014 cation, and recommend a robust approach to accurately measure SNP, gene and isoform Accepted: April 9, 2015 ASE through the use of personalized haplotype genome alignment, strict alignment quality control and intragenic SNP aggregation. -
UNC93A (NM 018974) Human Tagged ORF Clone – RC217002L3
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC217002L3 UNC93A (NM_018974) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: UNC93A (NM_018974) Human Tagged ORF Clone Tag: Myc-DDK Symbol: UNC93A Synonyms: dJ366N23.1; dJ366N23.2; Unc-93A Vector: pLenti-C-Myc-DDK-P2A-Puro (PS100092) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC217002). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_018974 ORF Size: 1371 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 UNC93A (NM_018974) Human Tagged ORF Clone – RC217002L3 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_018974.2 RefSeq Size: 2011 bp RefSeq ORF: 1374 bp Locus ID: 54346 UniProt ID: Q86WB7 Protein Families: Transmembrane MW: 50.1 kDa This product is to be used for laboratory only. -
Case Report an Adolescent with a Rare De Novo Distal Trisomy 6P and Distal Monosomy 6Q Chromosomal Combination
Hindawi Case Reports in Genetics Volume 2020, Article ID 8857628, 8 pages https://doi.org/10.1155/2020/8857628 Case Report An Adolescent with a Rare De Novo Distal Trisomy 6p and Distal Monosomy 6q Chromosomal Combination Leia A. Peterman , Gail H. Vance, Erin E. Conboy, Katelynn Anderson, and David D. Weaver Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA Correspondence should be addressed to David D. Weaver; [email protected] Received 15 April 2020; Revised 11 August 2020; Accepted 23 August 2020; Published 31 August 2020 Academic Editor: Silvia Paracchini Copyright © 2020 Leia A. Peterman et al. (is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We report on a 12-year-old female with both a partial duplication and deletion involving chromosome 6. (e duplication involves 6p25.3p24.3 (7.585 Mb) while the deletion includes 6q27q27 (6.244 Mb). (is chromosomal abnormality is also described as distal trisomy 6p and distal monosomy 6q. (e patient has a Chiari II malformation, hydrocephalus, agenesis of the corpus callosum, microcephaly, bilateral renal duplicated collecting system, scoliosis, and myelomeningocele associated with a neurogenic bladder and bladder reflux. Additional features have included seizures, feeding dysfunction, failure to thrive, sleep apnea, global de- velopmental delay, intellectual disability, and absent speech. To our knowledge, our report is just the sixth case in the literature with concomitant distal 6p duplication and distal 6q deletion. Although a majority of chromosomal duplication-deletion cases have resulted from a parental pericentric inversion, the parents of our case have normal chromosomes. -
The Genetic Program of Pancreatic Beta-Cell Replication in Vivo
Page 1 of 65 Diabetes The genetic program of pancreatic beta-cell replication in vivo Agnes Klochendler1, Inbal Caspi2, Noa Corem1, Maya Moran3, Oriel Friedlich1, Sharona Elgavish4, Yuval Nevo4, Aharon Helman1, Benjamin Glaser5, Amir Eden3, Shalev Itzkovitz2, Yuval Dor1,* 1Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 2Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3Department of Cell and Developmental Biology, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel 4Info-CORE, Bioinformatics Unit of the I-CORE Computation Center, The Hebrew University and Hadassah, The Institute for Medical Research Israel- Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 5Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel *Correspondence: [email protected] Running title: The genetic program of pancreatic β-cell replication 1 Diabetes Publish Ahead of Print, published online March 18, 2016 Diabetes Page 2 of 65 Abstract The molecular program underlying infrequent replication of pancreatic beta- cells remains largely inaccessible. Using transgenic mice expressing GFP in cycling cells we sorted live, replicating beta-cells and determined their transcriptome. Replicating beta-cells upregulate hundreds of proliferation- related genes, along with many novel putative cell cycle components. Strikingly, genes involved in beta-cell functions, namely glucose sensing and insulin secretion were repressed. Further studies using single molecule RNA in situ hybridization revealed that in fact, replicating beta-cells double the amount of RNA for most genes, but this upregulation excludes genes involved in beta-cell function.